A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy

Status Recruiting

Clinical Trial Summary

This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with active pathological changes,including crescents,necrosis and microthrombus.

Clinical Trial Description

It has been reported that for urinary protein excretion that is persistently more than 1g/24h and eGFR＞50ml/min/1.73m2 in IgA nephropathy(IgAN), the KDIGO guidelines suggest a 6-month course of glucocorticoids. The famous study by Pozzi C has proved that for patients of IgAN with proteinuria of 1.0-3.5g/24h and serum creatinine concentrations of 133 umol/L or less, a 6-month course of steroid treatment(1g/d methylprednisolone intravenously for 3 consecutive days,with the course repeated 2 months and 4 months later,then oral prednisone 0.5mg/kg/d on alternate days for 6 months) could significantly reduce proteinuria and protect against renal function deterioration in IgAN. Furthermore, as we know, active pathological changes in IgAN,including crescents,necrosis and microthrombus,which may turn fibrosis after three months would effect the prognosis.This will be a prospective, randomized, controlled, multi-center study. Patients in treatment group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd month ,then oral methylprednisolone 0.4mg/kg/d on consecutive days Patients in control group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-3rd-5th month ,then oral methylprednisolone 0.4mg/kg/d on consecutive days. After followed-up for 6 months, the curative effect of steroid therapy on proteinuria and the progression of IgAN will be evaluated. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02160132
Study type	Interventional
Source	Sun Yat-sen University
Contact	Zongpei Jiang, M.D. & Ph.D.
Phone	8620-38379727
Email	jx.home@medmail.com.cn
Status	Recruiting
Phase	Phase 2
Start date	June 2014
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03841448` - A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)	Phase 2
Recruiting	`NCT04020328` - Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency	Phase 4
Completed	`NCT02232776` - Efficacy and Safety of Losartan in Children With Ig A Nephropathy	Phase 3
Recruiting	`NCT04092491` - Study of the IgA Repertoire During IgA Deposition Nephropathy.
Not yet recruiting	`NCT05797051` - Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Recruiting	`NCT05791162` - Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy	N/A
Terminated	`NCT02647255` - Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy	Phase 2/Phase 3
Recruiting	`NCT01184599` - A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy	Phase 4
Active, not recruiting	`NCT00378443` - ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT	N/A
Completed	`NCT00396721` - Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy	Phase 2
Recruiting	`NCT01802034` - Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
Completed	`NCT00446251` - Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant	Phase 2
Active, not recruiting	`NCT04663204` - A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy	Phase 2
Not yet recruiting	`NCT05510323` - Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD	Phase 3
Completed	`NCT00521508` - Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy	N/A
Completed	`NCT00446459` - Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms